The estimated Net Worth of Ventures Viii, L.P.Cavanaug... is at least $18.3 Milhão dollars as of 5 February 2014. Ventures Cavanaug owns over 297,058 units of Trevena Inc stock worth over $18,322,420 and over the last 11 years Ventures sold TRVN stock worth over $0.
Ventures has made over 1 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Ventures bought 297,058 units of TRVN stock worth $2,079,406 on 5 February 2014.
The largest trade Ventures's ever made was buying 297,058 units of Trevena Inc stock on 5 February 2014 worth over $2,079,406. On average, Ventures trades about 297,058 units every 0 days since 2014. As of 5 February 2014 Ventures still owns at least 2,446,251 units of Trevena Inc stock.
You can see the complete history of Ventures Cavanaug stock trades at the bottom of the page.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire, ePartners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: